An open-label study of TAK-536 in patients with grade III hypertensio

Phase 3

• Conditions: Hypertension

• Registration Number: JPRN-jRCT2080220836
• Lead Sponsor: Takeda Pharmaceutical Company Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Grade III hypertension, etc.

Exclusion Criteria

1.Hypertensive emergency or renovascular hypertension
2.Cardiac disease, cerebrovascular disorder, vascular disease, or advanced hypertensive retinopathy
3.Hyperkalemia, etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified